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Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using
matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secuk-
inumab were matched to published aggregate data for infliximab by key baseline characteristics, with
matchingweights determined by logistic regression, and used to recalculate American College of Rheuma-
tology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differ-
ences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52,
ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50
responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term,
patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving
infliximab.
First draft submitted: 7 December 2018; Accepted for publication: 7 February 2019; Published online:
26 February 2019
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For patients with active psoriatic arthritis (PsA), the European League Against Rheumatism [1] and the Group
for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) [2] recommend the use of biologic
disease-modifying anti-rheumatic drugs (bDMARDs) when response to conventional synthetic disease-modifying
antirheumatic drugs is inadequate. Until 2016, the approved biologic disease-modifying anti-rheumatic drugs of
choice were the TNF inhibitors (TNFis) infliximab, adalimumab, golimumab, etanercept and certolizumab pegol,
as well as ustekinumab, a monoclonal antibody (mAb) targeted against IL-12/23. More recently, secukinumab and
ixekizumab, which are mAbs targeting IL-17A, as well as the IgG1-CTLA-4 fusion protein abatacept, have been
approved for the treatment of patients with PsA [3–8]. Studies to date have shown that secukinumab has a good
safety profile, and is associated with rapid and sustained improvement of the signs and symptoms of PsA, higher
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response rates, in terms of at least 20% improvement in American College of Rheumatology response criteria (ACR
20), and less radiographic progression when compared with placebo [9–11].
In the absence of data from direct, head-to-head (H2H) randomized controlled trials (RCTs), adjusted indirect
treatment comparisons can aid clinicians and health technology assessment bodies when making treatment and
reimbursement decisions. The number of placebo-controlled trials in rheumatology is increasing, but few H2H
studies have been conducted; consequently, indirect treatment comparisons are becoming more common in the
field [12]. Network meta-analysis can be used when a common comparator arm between RCTs (typically placebo)
is available; however, this method relies on analyzing aggregate data and therefore must assume that the trial
populations are similar. This can lead to potential bias in the presence of uneven treatment effect modifiers [12].
Furthermore, owing to the requirement for a common comparator arm, network meta-analyses are usually limited
to placebo-adjusted comparisons, and therefore cannot be used to assess long-term efficacy using trials in PsA, in
which patients typically receive placebo for 24 weeks or less [12,13]. By incorporating individual patient data (IPD),
matching-adjusted indirect comparison (MAIC) avoids some of the limitations imposed by cross-trial differences,
such as disparities between populations, lack of common comparators, sensitivity to modeling assumptions and
different definitions or reporting methods for outcome measures [13]. By using MAIC, a direct comparison of two
therapies can be simulated and extended beyond the placebo-controlled time points of the trials [14].
Health technology assessment agencies have acknowledgedMAIC as a valid and robust method when differences
between trial populations are present, andmethodological guidelines for the technique have been published [12,14,15].
Previously,MAIChas provided evidence for the comparative effectiveness of secukinumab, etanercept and infliximab
versus adalimumab in patients with psoriasis and PsA [16–18].
In this study, we aimed to assess the comparative effectiveness of biologic therapy in biologic-naive patients with
PsA, examining outcomes at time points up to 1 year. This paper is one of a series of studies using MAIC to
indirectly compare secukinumab to a range of TNFis. In this instance, MAIC was used to compare intravenous
infliximab, a chimeric mAb against TNF, with subcutaneously administered secukinumab, a fully human mAb
against IL-17A, using aggregate data from the IMPACT 2 trial [19] and pooled IPD from the FUTURE 2 [9]
and FUTURE 3 [10] trials. Using MAIC methodology, the trial from which aggregate data are taken provides
the target population for the study; in our analysis, this meant that patients naive to TNFi treatment were the
population of interest. TNFi exposure is likely to be an effect modifier [20]; differences in treatment effects between
TNFi-naive and TNFi-experienced patients have been reported. Therefore, it is valuable to compare secukinumab
and infliximab specifically in a TNFi-naive population.
Patients & methods
Matching-adjusted indirect comparison
The MAIC process comprises the following steps: identification of source data by systematic literature review
(SLR); selection of baseline characteristics for matching; matching and adjusting IPD to published aggregate data;
and comparing outcomes from IPD with aggregate data. The datasets analyzed in the current study are available
from the corresponding author on reasonable request.
Identification of source data by SLR
An SLR with a cut-off in November 2015 was used to identify relevant clinical evidence for secukinumab and
infliximab in the treatment of adult patients with PsA, as described previously [20]. Following full-text screening, 29
trials were considered to be suitable for inclusion according to the eligibility criteria (Supplementary Table 1 and
Supplementary Figure 1). Of these trials, 18 included neither secukinumab nor infliximab and hence were excluded.
The remaining 11 RCTs are shown in Supplementary Table 2. Of these, nine were excluded because patients did
not receive the approved doses of secukinumab (subcutaneous 150 and 300 mg) or infliximab (5 mg/kg) [1]. The
RCTs identified for inclusion were FUTURE 2 (NCT01752634) [9] and IMPACT 2 (NCT00051623) [19].
More recently, data from the FUTURE 3 trial (NCT01989468), with 1-year follow-up, have been published [10],
andwere considered potentially suitable for inclusion in our analysis. To confirmwhether any newdata for infliximab
had been published in the same time period, a targeted literature search in PubMed covering the time period from
the last SLR update to April 2018 using the keywords ‘infliximab’ and ‘psoriatic arthritis’ revealed no new placebo-
controlled infliximab trials or H2H studies directly comparing secukinumab with infliximab in PsA. Additionally,
no ongoing studies matching our inclusion criteria were detected in a search of the ClinicalTrials.gov website in
April 2018 using the keywords ‘infliximab’ and ‘psoriatic arthritis’.
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FUTURE 3 had a similar design to that of FUTURE 2 (and importantly used the approved dosages of
secukinumab 150 and 300 mg). Secukinumab was administered subcutaneously using an autoinjector in FUTURE
3, whereas in FUTURE 2 a prefilled syringe was used. The potential for a small effective sample size (ESS) following
matching is a known limitation of MAIC [12]; therefore, to maximize the ESS in our study, we decided to use pooled
IPD from the FUTURE 2 and FUTURE 3 studies. Pooling IPD to match to aggregate data is a valid methodology
to increase the potential ESS in a MAIC [13,21].
Studies included
FUTURE 2 [9] and FUTURE 3 [10] were both Phase III RCTs (Figure 1). In FUTURE 2, patients were
randomized 1:1:1:1 to receive subcutaneous secukinumab 75, 150 or 300 mg, or placebo [9]. In FUTURE 3,
patients were randomized 1:1:1 to receive subcutaneous secukinumab 150 or 300 mg, or placebo. Patients who had
previously experienced TNFi incomplete response (TNFi-IR) were included, with up to three treatment failures
being admissible. IMPACT 2 was also a Phase III RCT (Figure 1) [19]. Patients were randomized 1:1 to receive
intravenous infusions of either infliximab 5 mg/kg or placebo. The primary end point was achievement of an ACR
20 response at week 14 [19].
Selection of baseline characteristics for matching
The selection of baseline characteristics for matching (including prognostic variables and effect modifiers) has been
described previously [20]. Two scenarios were developed that differed in the combination of included matching
variables. First, a principal analysis (Table 1) included established prognostic variables reported in previous MAICs
in PsA [18,20], but incorporated one additional parameter (TNFi-IR), identified by logistic regression analysis as
a key effect modifier, as detailed in our previous study [20]. Previous TNFi exposure is also likely to be an effect
modifier for infliximab: it has been established that patients with PsA who switch between TNFi therapies have
lower ACR responses with subsequent TNFis than TNFi-naive patients [22–25].
A sensitivity analysis (Supplementary Table 3) was performed, and included all matching variables used in the
principal analysis plus three additional important clinical characteristics to increase the matching stringency: PsA
disease duration (time since diagnosis), swollen joint count (SJC) and baseline CRP levels.
Matching & adjusting individual patient data to published aggregate data & comparing outcomes
TheMAIC matching process is shown in Figure 2. IPD from the pooled secukinumab 150 and 300 mg arms of the
FUTURE 2/3 RCTs were weighted to match the selected patient baseline characteristics for the infliximab arm of
IMPACT 2, for which aggregate data were taken from the trial publication [19]. Placebo arms were also matched.
The methodology was based on Signorovitch et al. [26] and subsequent publications [16,27,28], and methodological
guidelines were followed [14]. After this matching process, the weighted mean baseline characteristics of the pooled
FUTURE 2/3 populations were identical to those reported for IMPACT 2. Consequently, the matching resulted
in a lower ESS for the FUTURE 2/3 arms. SAS version 9.4 and R version 3.2.1 were used for the analysis.
After matching, outcomes in the reweighted FUTURE 2/3 population were compared with outcomes reported
in IMPACT 2. Given that the comparison was conducted in a population matched to IMPACT 2, the target
population or clinical context, of our comparison was restricted to TNFi-naive patients with characteristics similar
to those in the IMPACT 2 trial.
Analyses
Reporting of missing data
In IMPACT 2, all published outcomes included in this MAIC were from the intention-to-treat population, as were
those from FUTURE 2/3. All missing ACR data were handled using nonresponder imputation [19], except at week
54/52 when missing data were based on observed data. Scores from the 36-item Short-Form health hurvey (SF-36)
were derived from the secukinumab arms using last observation carried forward for missing data at all time points
to match the available data from IMPACT 2. To ensure the robustness of these analyses, ACR 20 responses and
odds ratios (ORs) at week 54/52 were also estimated by alternative imputation methods. Given that IMPACT 2
outcome data at week 6 were reported in graphs only, specific software (DigitizeIt, Braunschweig, Germany) was
used for data extraction.
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Primary endpoint
(ACR 20)
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(ACR 20)
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FUTURE 2
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Patients with
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FUTURE 3
TNFi-naïve
patients
Patients with
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to TNFis
IMPACT 2
TNFi-naïve
patients
14 16 24 545286
Shared unbiased
placebo phase  
100
¶ ¶
100
Primary
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(ACR 20)
Infliximab 5 mg/kg
Placebo
Infliximab 5 mg/kg or 10 mg/kg§
Uptitration to infliximab 10 mg/kg for
non-responders 
Early escape§
99
100
Secukinumab 150 mg or 300 mg PFS
R
1:1‡
98
Placebo
Placebo†
Secukinumab 150 mg 
or 300 mg PFS
R
1:1
Secukinumab 75 mg
Secukinumab 150 mg 
100
Secukinumab 300 mg 
R
1:1:1:1
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R
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Placebo
Secukinumab 150 mg 
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1:1
Secukinumab 150 mg AI
Secukinumab 300 mg AI 
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Figure 1. FUTURE 2, FUTURE 3 and IMPACT 2 trial designs.
†Patients who had ≥20% improvement from baseline in TJC and SJC.
‡Patients who had <20% improvement from baseline in TJC and SJC.
§Patients randomized to infliximab 5 mg/kg who had <20% improvement from baseline in the combined number of SJC and TJC had
their infliximab dose increased to 10 mg/kg at weeks 38 and 46; 15 patients received an uptitration in their dose of infliximab from
5 mg/kg to 10 mg/kg.
¶Patients who had <10% improvement from baseline in both SJC and TJC received infliximab 5 mg/kg. The placebo-adjusted comparison
was only possible until week 16 (shown by yellow rectangle) because patients in all trials could receive active treatment from this point
onward. Numbers at the heads of the grey arrows on the left denote the ITT populations.
ACR: American College of Rheumatology; ACR 20: At least a 20% improvement according to the ACR response criteria; AI: Auto-injector;
ITT: Intent-to-treat; MAIC: Matching-adjusted indirect comparison; PFS: Prefilled syringe; R: Randomization; SJC: Swollen joint count; TJC:
Tender joint count; TNFi: TNF inhibitor.
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Figure 2. Matching-adjusted indirect comparison methodology infographic.
†Weights were derived by logistic regression. The choice of matching parameters was made by consensus of all
authors (who include both clinical and methodological experts). Patients were matched for key characteristics known
or expected to influence clinical outcomes in individuals with PsA.
‡Pooled placebo arms of FUTURE 2 and FUTURE 3 were also matched to the placebo arm of IMPACT 2.
ESS: Effective sample size; PsA: Psoriatic arthritis; SEC: Secukinumab.
Outcomes
ACR 20/50/70 responses and SF-36 scores were selected for comparison in line with the Outcomes Measures in
Rheumatology (OMERACT) [29] and GRAPPA [30] guidelines on outcome measures that should be included in
RCT datasets in PsA [29]. Comparisons were made between outcomes at the closest available time points in the
two trials. ACR response criteria encompass a number of disease domains, including tender joint count and SJC,
patient global assessment, pain and physical function, and acute phase response, and therefore represent a stringent
outcome measure.
Health-related quality of life was measured using SF-36, which comprises eight domains that can be aggregated
into two summary measures: the physical (PCS) and mental component summary (MCS) scores. The PCS is
calculated by weighting the four physical and vitality domains positively and the remaining three mental domains
negatively. To calculate the MCS, the four mental domains are positively weighted and the physical domains are
negatively weighted. These are presented as mean changes from baseline (CFBs).
Placebo-adjusted & non-placebo-adjusted outcome comparisons
Placebo-adjusted comparisons (anchored) were only possible until week 16, as all patients randomized to placebo
could potentially receive active rescue treatment from week 16 onward in all three trials. Owing to the lack of
placebo as common comparator after week 16, non-placebo-adjusted (unanchored) outcomes from the infliximab
arm of IMPACT 2 were directly compared with recalculated outcomes from the secukinumab 150 and 300 mg
pooled arms of FUTURE 2/3.
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Pairwise comparisons
ACR responses – For the analysis at weeks 6/8 and 14/16 (placebo-adjusted), ORs for the secukinumab arm versus
the placebo arm in the reweighted FUTURE 2/3 population were derived from a logistic regression model by
using generalized estimating equations with robust standard errors, as recommended by Signorovitch et al. and the
National Institute for Health and Care Excellence (NICE) guidance on MAIC methodology [14,26]. Generalized
estimating equations were fitted using PROC GENMOD in SAS. These placebo-adjusted OR values were used to
estimate the comparative effectiveness of secukinumab and infliximab using the method of Bucher et al. [31]. By
using linear predictor scales such as ORs instead of comparing natural outcome scales such as ACR 20 responses,
we complied with a mandatory requirement of NICE [14,15].
For non-placebo-adjusted comparisons, standard errors for OR values were estimated based on the information
provided by a 2 × 2 contingency table that showed outcomes in the infliximab arm of the IMPACT 2 trial and
outcomes in the recalculated pooled secukinumab arm of FUTURE 2/3.
Psoriasis area and severity index (PASI) outcomes – We did not report PASI data because baseline characteristic
data for the IMPACT 2 trial psoriasis subgroup were not available. This meant that uncontrolled imbalances could
persist postmatching. It is also worth noting that PASI data were collected only in a subgroup of patients in both
RCT populations (patients with psoriasis affecting ≥3% body surface area); consequently, missing data in the
non-PASI-matched population could further compound this study bias.
SF-36 summary scores – A 95% CI around mean changes in scores for patients in the infliximab arm of the
IMPACT 2 trial was estimated using the normal approximation. The p-values for the differences in mean change
scores between secukinumab and infliximab were calculated using a Z-statistic, which divides the difference in
mean changes in scores by the combined standard error.
Results
Principal analysis
Matching baseline characteristics
Table 1 shows the baseline characteristics of patients in the pooled FUTURE 2/3 population before matching
(secukinumab 150 mg, n = 238; secukinumab 300 mg, n = 239; placebo, n = 235) and after matching to the
IMPACT 2 infliximab (n = 100) and placebo (n = 100) arms. Before matching, a key difference between patient
populations was the proportion who were TNFi-naive (secukinumab 150 mg, 66.0%; secukinumab 300 mg,
67.8%; placebo [FUTURE 2/3], 66.4%; infliximab, 100.0%; placebo [IMPACT 2], 100.0% [p < 0.0001]). After
matching, all patients were TNFi-naive. Similar observations were made for all matching variables in the principal
(Table 1) and sensitivity analyses (Supplementary Table 3). Therefore, although there was heterogeneity in the
patient populations between FUTURE 2/3 and IMPACT 2 before matching, parameters were more similar after
matching, with a reduced ESS for FUTURE 2/3 (secukinumab 150 mg, 84; secukinumab 300 mg, 70; placebo,
41).
ACR responses
Figures 3 and 4 and Table 2 show ACR 20/50/70 responses for secukinumab 150 mg and infliximab 5 mg/kg,
for both placebo-adjusted (weeks 6/8 and 14/16) and non-placebo-adjusted (weeks 24 and 54/52) time points.
There were no differences in ACR responses between secukinumab 150 mg and infliximab at weeks 6/8 and 14/16
(both placebo-adjusted). At week 24, secukinumab 150 mg was associated with higher ACR 20 responses than
infliximab (OR [95% CI]: 2.31 [1.24–4.29]; p = 0.008). Week 54/52 non-placebo-adjusted ACR 20 responses
were also higher with secukinumab 150 mg than infliximab (OR [95% CI]: 3.03 [1.52–6.04]; p = 0.002).
As shown in Figures 3 and 4 and Table 2, there was no evidence of differences in ACR 20/50/70 responses
between secukinumab 300mg and infliximab at weeks 6/8 and 14/16 (both placebo-adjusted) and at week 24 (non-
placebo-adjusted). At week 54/52, non-placebo-adjusted ACR 20/50 responses were higher with secukinumab
300mg than infliximab (OR [95%CI]: 2.72 [1.33–5.57]; p = 0.006, and 2.69 [1.41–5.11]; p = 0.003, respectively).
These observations were unchanged when alternative imputation methods were applied (Supplementary Table 4).
Table 2 shows ORs and p-values for all ACR comparisons, including interpretations using the p-value range
between 0.1 and 0.001.
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Figure 3. ACR 20, ACR 50 and ACR 70 response rates for secukinumab 150 mg, secukinumab 300 mg and infliximab 5 mg/kg (principal
analysis).
For non-placebo-adjusted comparisons, ACR 20, ACR 50 and ACR 70 responses are the absolute mean response rate (IMPACT 2) and the
predicted mean response rate (FUTURE 2/3). For placebo-adjusted comparisons, the numbers represent differences in response rates
between active treatment and placebo. Error bars show 95% CI. Week 52 FUTURE 2/3 secukinumab intent-to-treat population (observed
values) was compared with week 54 IMPACT 2 infliximab intent-to-treat population (missing equals failure/missing values excluded).
p-values are presented at the 5% significance threshold, and are derived from odds ratio values.
ACR: American College of Rheumatology; ACR 20/50/70: At least a 20, 50 or 70% improvement according to the ACR response criteria;
ESS: Effective sample size; INF: Infliximab; SEC: Secukinumab.
10.2217/cer-2018-0141 J. Comp. Eﬀ. Res. (Epub ahead of print) future science group
SEC vs INF in psoriatic arthritis: MAIC Research Article
Week 6/8
Week 14/16
Week 24
Week 54/52
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00
Week 6/8
Week 14/16
Week 24
Week 54/52
Odds ratio
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00
Odds ratio
Figure 4. American College of Rheumatology 20 odds ratios for secukinumab 150 mg and secukinumab 300 mg versus infliximab
(principal analysis) for all time points.
(A) Secukinumab 150 mg versus infliximab; (B) secukinumab 300 mg versus infliximab.
Error bars show 95% CI. Week 52 FUTURE 2/3 secukinumab intent-to-treat population (observed values) was compared with week 54
IMPACT 2 infliximab intent-to-treat population (missing equals failure/missing values excluded). In FUTURE 2/3, patients receiving
placebo who did not achieve ≥20% improvement compared with baseline in TJC or SJC by week 16 were rerandomized 1:1 to
secukinumab 150 or 300 mg; those who did achieve this response were rerandomized 1:1 at week 24. In IMPACT 2, patients receiving
placebo who had <10% improvement from baseline in both SJC and TJC at week 16 received infliximab 5 mg/kg. Patients randomized to
infliximab 5 mg/kg who had <20% improvement from baseline in the combined number of SJC and TJC had their infliximab dose
increased to 10 mg/kg at weeks 38 and 46; 15 patients received an uptitration in their dose of infliximab from 5 to 10 mg/kg.
SJC: Swollen joint count; TJC: Tender joint count.
Changes in SF-36 PCS & MCS scores
Table 3 shows mean CFBs in SF-36 PCS and MCS scores with secukinumab 150 and 300 mg compared with
infliximab. There was evidence of greater improvement with infliximab (mean CFB [95% CI]: 8.0 [5.5–10.5])
than secukinumab 150 mg (mean CFB [95% CI]: 4.7 [3.3–6.0]; p = 0.019) and secukinumab 300 mg (mean CFB
[95% CI]: 4.3 [3.0–5.6]; p = 0.009) at week 14/16 in terms of placebo-controlled changes in SF-36 PCS scores,
although these were not maintained at weeks 24 and 54/52. These results were not supported by sensitivity analysis
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Table 2. ACR 20, ACR 50 and ACR 70 response rates (odds ratios) for secukinumab 150 mg and secukinumab 300 mg
versus infliximab (principal analysis).
SEC 150 mg vs INF SEC 300 mg vs INF
ACR 20 ACR 50 ACR 70 ACR 20 ACR 50 ACR 70
Week 6 (IMPACT 2)/week 8 (FUTURE 2/3), placebo-adjusted data
0.77
(0.26–2.27)
p = 0.630
0.30
(0.05–1.72)
p = 0.177
NE‡ 0.56
(0.19–1.70)
p = 0.310
0.43
(0.07–2.45)
p = 0.340
NE‡
Week 14 (IMPACT 2)/week 16 (FUTURE 2/3), placebo-adjusted data
1.40
(0.48–4.07)
p = 0.539
0.77
(0.16–3.83)
p = 0.754
0.37
(0.03–4.67)
p = 0.441
0.84
(0.29–2.47)
p = 0.749
1.21
(0.24–6.03)
p = 0.816
0.83
(0.07–10.45)
p = 0.888
Week 24, non-placebo-adjusted data
2.31
(1.24–4.29)
p = 0.008§
1.05
(0.58–1.90)
p = 0.865
0.91
(0.47–1.76)
p = 0.769
1.81
(0.96–3.43)
p = 0.068
1.29
(0.70–2.39)
p = 0.412
0.95
(0.48–1.90)
p = 0.888
Week 54 (IMPACT 2)/week 52 (FUTURE 2/3),†non-placebo-adjusted data
3.03
(1.52–6.04)
p = 0.002§
1.40
(0.77–2.58)
p = 0.273
1.04
(0.51–2.12)
p = 0.914
2.72
(1.33–5.57)
p = 0.006§
2.69
(1.41–5.11)
p = 0.003§
1.86
(0.92–3.73)
p = 0.083
Data are shown as odds ratio (95% CI). Two-sided p-values (bold text when p  0.05) were derived from odds ratio values using the Z-statistic. Italic text indicates increasing evidence
(0.1  p  0.001) using an updated statistical interpretation. Note that no p-values indicating strong evidence (p ≤ 0.001) were observed.
†Observed data at week 54/week 52.
‡Odds ratios cannot be calculated because the proportion of ACR 70 responders in the IMPACT 2 placebo arm is 0.
§Evidence of higher outcomes for SEC than for INF.
ACR: American College of Rheumatology; ACR 20/50/70: At least a 20, 50 or 70% improvement according to the ACR response criteria; INF: Infliximab; NE: Not estimable; SEC:
Secukinumab.
Table 3. SF-36 scores for infliximab, secukinumab 150 mg and secukinumab 300 mg (principal analysis).
SF-36 score IMPACT 2
INF 5 mg/kg
FUTURE 2/3
SEC 150 mg
FUTURE 2/3
SEC 300 mg
Placebo-
adjusted
Non-placebo-adjusted Placebo-
adjusted
Non-placebo-adjusted Placebo-
adjusted
Non-placebo-adjusted
Week 14/16
(INF, n = 100;
PBO, n = 100)
Week 24
(n = 100)
Week 54/52†
(n = 84)
Week 14/16
(SEC, ESS = 84;
PBO, ESS = 41)
Week 24
(SEC, ESS = 84)
Week 54/52†
(SEC, ESS = 84)
Week 14/16
(SEC, ESS = 70;
PBO, ESS = 41)
Week 24
(SEC, ESS = 70)
Week 54/52†
(SEC, ESS = 70)
SF-36 PCS
score, mean
change from
baseline (95%
CI)
8.0
(5.5–10.5)
7.7
(5.8–9.6)
8.8
(6.5–11.1)
4.7
(3.3–6.0)
p = 0.019‡
7.3
(6.4–8.2)
p = 0.724
7.8
(6.7–8.8)
p = 0.413
4.3
(3.0–5.6)
p = 0.009‡
6.7
(5.7–7.7)
p = 0.380
7.8
(6.8–8.8)
p = 0.419
SF-36 MCS
score, mean
change from
baseline (95%
CI)
5.0
(2.2–7.8)
3.9
(1.6–6.2)
3.7
(1.7–5.7)
5.7
(4.0–7.4)
p = 0.691
6.4
(5.1–7.7)
p = 0.066
5.7
(4.4–6.9)
p = 0.103
3.2
(1.3–5.2)
p = 0.315
4.0
(2.5–5.5)
p = 0.965
4.8
(3.4–6.3)
p = 0.375
Bold text indicates statistically significant differences (p  0.05) in mean changes from baseline between SEC and INF. Italic text indicates increasing evidence (0.1  p  0.001) using an
updated statistical interpretation. Note that no p-values indicating strong evidence (p ≤ 0.001) were observed.
†LOCF imputation used.
‡Evidence of higher outcomes for INF than for SEC.
ESS: Effective sample size; INF: Infliximab; LOCF: Last observation carried forward; MCS: Mental component summary; PBO: Placebo; PCS: Physical component summary; SEC: Secukinumab;
SF-36: 36-item Short-Form health survey.
(below) and should therefore be considered with caution. There were no differences in MCS scores at any time
points in the principal analysis. These observations were consistent when data were interpreted using the p-value
range between 0.1 and 0.001 (Table 3).
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Sensitivity analysis
Matching baseline characteristics
The sensitivity analysis matched data using the same parameters as the principal analysis, with addition of PsA
disease duration and baseline SJC and CRP levels, as shown in Supplementary Table 3. The ESSs for FUTURE
2/3 after matching were 49 for secukinumab 150 mg, 32 for secukinumab 300 mg and 27 for placebo.
ACR responses
The results of the sensitivity analysis were consistent with those of the principal analysis (Supplementary Figure
2and Supplementary Table 5). ACR 20 responses were higher with secukinumab 150 mg than infliximab at weeks
24 and 54/52 during the non-placebo-adjusted period (OR [95% CI]: 3.03 [1.39–6.63]; p = 0.005, and 3.87
[1.60–9.36]; p = 0.003, respectively). ACR 20 and ACR 50 responses were higher with secukinumab 300 mg
than infliximab at week 54/52 (OR [95% CI]: 2.74 [1.05–7.15]; p = 0.039, and 3.04 [1.32–7.04]; p = 0.009,
respectively). These observations were consistent when data were interpreted using the p-value range between 0.1
and 0.001 (Supplementary Table 5).
Changes in SF-36 PCS & MCS scores
The results of this analysis are shown in Supplementary Table 6. In the sensitivity analysis, there was no difference
in SF-36 PCS scores between infliximab and secukinumab at week 14/16 (placebo-adjusted) and subsequent time
points during the non-placebo-adjusted period.
At week 24 (non-placebo-adjusted), there was evidence of improvements in non-placebo-controlled SF-36 MCS
scores with secukinumab 150 mg compared with infliximab (mean CFB [95% CI]: 6.8 [1.6–6.2] vs 3.9 [5.6–8.0];
p = 0.032). No differences between treatments were evident at weeks 14/16 (placebo-adjusted) and 54/52 (non-
placebo-adjusted). These observations were consistent when data were interpreted using the p-value range between
0.1 and 0.001 (Supplementary Table 6).
Discussion
This study usesMAIC to assess the comparative effectiveness of the IL-17A inhibitor secukinumab (at two clinically
relevant subcutaneously administered dosages: 150 mg and 300 mg) and the TNFi infliximab, intravenously
administered, in TNFi-naive patients with active PsA [14,32]. Although the RCTs from which the data were taken
were conducted at different times, the key features of the study designs were very similar. By allowing matching of
populations according to baseline characteristics, the MAIC methodology was able to adjust for the differences in
patient populations between the earlier study on infliximab and the later studies on secukinumab.
In our MAIC, no differences in ACR responses were observed between secukinumab and infliximab during
the first 14 weeks. Advantages in favor of secukinumab were seen after 24 weeks of treatment, in terms of ACR
20/50 responses, when compared with infliximab. This is in agreement with a recent MAIC analysis suggesting
that patients with PsA receiving secukinumab are more likely to achieve higher mid- to long-term ACR responses
than those treated with the TNFi adalimumab [17].
The results of our principal analysis are largely supported by the sensitivity analyses, which used three addi-
tional matching variables (duration of PsA, SJC and CRP levels) for increased matching stringency. However, we
acknowledge that findings not replicated in both analyses, such as SF-36 PCS, should be treated with caution when
drawing conclusions, because it is possible these do not reflect true differences in treatment effects.
In this study, we include binary (ACR) and continuous (SF-36 scores) outcomes, in line with OMERACT [29]
and GRAPPA guidance [30]. Our analyses comply with recent recommendations on the application of MAIC
methodology [14,15], employing linear predictor scales such as ORs instead of comparing natural outcomes such as
ACR 20 responses.
Health-related quality of life data are crucial for understanding how the clinical success of any therapy impacts
patients’ well-being and their ability to function in daily life. Evidence of a greater improvement in SF-36 PCS
scores with infliximab than secukinumab 150 and 300 mg at week 14/16 was not observed at later time points,
or replicated in the sensitivity analysis. It is worth noting that patients in the IMPACT 2 study had substantially
lower SF-36 PCS scores at baseline than patients in FUTURE 2 or FUTURE 3, which may increase the chances
that larger post-baseline changes would be reported.
The MAIC methodology has limitations. Although observed patient variables at baseline can be matched, it
is not possible to control for unobserved variables or variables reported in only one study. Results are also most
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relevant to patients similar to the matched IMPACT 2 trial population, namely TNFi-naive. Furthermore placebo
adjustment was feasible only until week 16 owing to differences in study designs, and week 24 was the only
common time point at which outcomes were reported in both RCTs. Although non-placebo-adjusted comparisons
are a legitimate means of comparing treatments using long-term data, adjustments cannot be made for unobserved
differences in trial populations or study design. A key difference in study design that could not be matched for
both placebo and active treatment arms is route of administration, which may have led to differences in placebo
responses. The reduced ESS for secukinumab must be acknowledged when interpreting our findings, although we
have made an effort to counteract this by using pooled IPD from FUTURE 2 and FUTURE 3, which resulted in
an acceptable sample size.
Conclusion
Our findings indicate that TNFi-naive patients with PsA have a similar probability of achieving ACR responses
with subcutaneous secukinumab or intravenous infliximab in the short term. In the same target population, our
findings indicate that there is a slightly higher probability of mid- to long-term ACR responses in those receiving
secukinumab rather than infliximab. This study should be treated as an interim comparison in the absence of
a confirmatory H2H RCT, and does not replace RCTs powered for a direct comparison between treatments. In
future, such discussions can inform the design of potential H2H RCTs between PsA treatments.
Summary points
• In the absence of a head-to-head randomized controlled trial, matching-adjusted indirect comparison was used
to compare subcutaneous secukinumab with intravenous infliximab in biologic-naive patients with PsA.
• Individual patient data from the FUTURE 2 and FUTURE 3 trials were matched to data from the IMPACT 2 trial
using key patient demographic and clinical characteristics. Logistic regression determined matching weights for
these variables.
• The relevant population in this comparison was TNFi-naive patients with characteristics similar to patients in the
IMPACT 2 trial.
• Recalculated secukinumab outcomes were compared with infliximab outcomes at weeks 6/8 and 14/16 (both
placebo-adjusted) and at weeks 24 and 54/52 (both non-placebo-adjusted).
• In terms of American College of Rheumatology (ACR) responses, there were no differences between secukinumab
and infliximab in the short term (weeks 6/8 and 14/16).
• At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab.
• At weeks 54/52, ACR 20/50 responses were higher with secukinumab 300 mg than infliximab.
• TNFi-naive patients with PsA have a similar probability of achieving ACR responses with subcutaneous
secukinumab or intravenous infliximab in the short term.
• In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than
those receiving infliximab.
Future perspective
• Head-to-head trials in PsA are being conducted to provide direct comparisons of treatments. Before these RCT
data are available, indirect treatment comparisons can provide interim data and inform trial design.
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